Thrombomodulin-protein C-EPCR system integrated to regulate coagulation and inflammation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 8, 2004, Pages 1374-1383

  Van De Wouwer, Marlies ^a   Collen, Désiré ^a   Conway, Edward M ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Cardiac Unit   (Belgium)

Author keywords

Endothelium; Hemostasis; Inflammation; Leukocytes; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; CELL RECEPTOR; CELL SURFACE PROTEIN; CHONDROITIN SULFATE; EPIDERMAL GROWTH FACTOR DERIVATIVE; PROTEIN C; PROTEIN C RECEPTOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SHORT SURVEY; STRESS; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; APOPTOSIS; BLOOD COAGULATION; CARBOXYPEPTIDASE U; ENDOTHELINS; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; INFLAMMATION; MICE; PAPIO; PROTEIN C; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SEPSIS; STRESS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOMODULIN;

EID: 3943060904     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000134298.25489.92     Document Type: Short Survey

References (120)

1. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004;24:41-53.
2. Ulutin ON, Seegers WH. Autoprothrombin II and autoprothrombin II anticoagulant. Thromb Diath Haemorrh. 1962;7:256-263.
3. Esmon CT, Stenflo J, Suttie JW. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem. 1976; 251:3052-3056.
4. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem. 1976;251: 355-363.
5. Kisiel W, Canfield WM, Ericsson EH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation of thrombin. Biochem. 1977;16:5824-5831.
6. Stenflo J, Fernlund P. Amino acid sequence of the heavy chain of bovine protein C. J Biol Chem. 1982;257:12180-12190.
7. Esmon CT, Esmon NL, Harris KW. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257:7944-7947.
8. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A. 1996;93:10212-10216.
9. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003;102:146-151.
10. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989;73:712-717.
11. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Eng J Med. 1984;310:559-561.
12. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995;74:449-453.
13. Taylor FJ, Chang A, Esmon CT, Hinshaw LB. Baboon model of Escherichia coli sepsis: Description of its four stages and the role of tumor necrosis factor, tissue factors, and the protein C system in septic shock. Curr Stud Hematol Blood Transfus. 1991;58:8-14.
14. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
15. Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000;95:1680-1686.
16. Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823-4827.
17. Kobayashi H, Gabazza EC, Taguchi O, Wada H, Takeya H, Nishioka J, Yasui H, Kobayashi T, Hataji O, Suzuki K, Adachi Y. Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med. 1998;157:1850-1854.
18. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
19. Bizios R, Lai L, Fenton JW, 2nd, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol. 1986;128: 485-490.
20. Drake WT, Lopes NN, Fenton JW, 2nd, Issekutz AC. Thrombin enhancement of interleukin-1 and tumor necrosis factor-α induced polymorphonuclear leukocyte migration. Lab Invest. 1992;67:617-627.
21. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester. J Immunol. 1994;153:3664-3672.
22. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276: 11199-11203.
23. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology. 1994;4:221-225.
24. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87:642-647.
25. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol. 1997; 272:L197-202.
26. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
27. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102:1499-1505.
28. Riewald M, Petrovan RJ, Donner A, Ruf W. Activated protein C signals through the thrombin receptor PARI in endothelial cells. J Endotoxin Res. 2003;9:317-321.
29. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338-342.
30. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003;373:65-70.
31. Bajzar L, Manuel R, Nesheim M. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
32. Nagashima M, Yin ZF, Broze GJ, Jr., Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front Biosci. 2002;7:d556-568.
33. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 2002;46:131-134.
34. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor: A potential regulator of vascular inflammation. J Biol Chem. 2003.
35. Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1981;256:5532-5535.
36. Esmon CT, Owen WG. The discovery of thrombomodulin. J Thromb Haemost. 2004;2:209-213.
37. Boffa M, Jackman R, Peyri N, Boffa J, George B. Thrombomodulin in the central nervous system. Nouv Rev Fr Hematol. 1991;33:423-429.
38. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem. 1988;104:628-632.
39. McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991;78:3128-3132.
40. Wong V, Hofman FM, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res. 1991;556:1-5.
41. Conway E, Nowakowski B, Steiner-Mosonyi M. Biologically active thrombomodulin is present in synovial fluid and elevated in effusions of patients with rheumatoid arthritis. Clin Res. 1992;40:241a.
42. Raife TJ, Lager DJ, Madison KC, Piette WW, Howard EJ, Sturm MT, Chen Y, Lentz SR. Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest. 1994;93:1846-1851.
43. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Weitz JI, Weiler-Guettler H, Carmeliet P, Collen D. Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. Blood. 1999;93:3442-3450.
44. Koyama T, Parkinson JF, Sié P, Bang NU, Müller BG, Preissner KT. Different glycoforms of human thrombomodulin-Their glycosaminoglycan- dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. Eur J Biochem. 1991;198: 563-570.
45. Hamada H, Ishii H, Sakyo K, Horie S, Nishiki K, Kazama M. The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood. 1995;86:225-233.
46. Tohda G, Oida K, Okada Y, Kosaka S, Okada E, Takahashi S, Ishii H, Miyamori I. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1998;18:1861-1869.
47. Kurosawa S, Stearns DJ, Jackson KW, Esmon CT. A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site. J Biol Chem. 1988;263:5993-5996.
48. Suzuki K, Hayashi T, Nishioka J, Kosaka Y, Zushi M, Honda G, Yamamoto S. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem. 1989;264:4872-4876.
49. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem. 1989;264:10351-10353.
50. Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem. 2000; 275:22942-22947.
51. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/ threonine-rich domain are required for cofactor activity. J Biol Chem. 1992;267:6164-6170.
52. Kokame K, Zheng X, Sadler J. Activation of thrombin-activatable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem. 1998;273:12135-12139.
53. Schenk-Braat EA, Morser J, Rijken DC. Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. Eur J Biochem. 2001;268:5562-5569.
54. DeMunk G, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (Pro-urokinase) by thrombomodulin. J Clin Invest. 1991;88:1680-1684.
55. Molinari A, Giorgetti C, Lansen J, Vaghi F, Orsini G, Faioni E, Mannucci P. Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator "in vitro" and in a perfused rabbit heart model. Thromb Haemost. 1992;67:226-232.
56. Suzuki K, Kusomoto H, Deyashiki Y, Hishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 1987;6:1891-1897.
57. Lu R, Esmon NL, Esmon CT, Johnson AE. The active site of the thrombin-thrombomodulin complex. J Biol Chem. 1989;264:12956-12962.
58. Weisel JW, Nagaswami C, Young TA, Light DR. The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem. 1996;271:31485-31490.
59. Villoutreix B, Dahlback B. Molecular model for the C-type lectin domain of human thrombomodulin. J Mol Model. 1998;4:310-322.
60. Fukudome K, Esmon C. Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). J Biol Chem. 1995;270:5571-5577.
61. Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med. 1998;187:1029-1035.
62. Laszik Z, Mitro A, Taylor FB, Jr., Ferrell G, Esmon CT. Human Protein C Receptor Is Present Primarily on Endothelium of Large Blood Vessels: Implications for the Control of the Protein C Pathway. Circulation. 1997;96:3633-3640.
63. Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem. 1987;262:611-616.
64. Espana F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res. 1991;64:309-320.
65. Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R, Geske R, Thung SN, Shenaq SM, Woo SL. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 1999;84:84-92.
66. Weiler H, Lindner V, Kerlin B, Isermann B, Hendrickson S, Cooley B, Meh D, Mosesson M, Shworak N, Post M, Conway E, Ulfman L, von Andrian U, Weitz J. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001;21:1531-1537.
67. Rijneveld AW, Weijer S, Florquin S, Esmon CT, Meijers JC, Speelman P, Reitsma PH, Ten Cate H, Van Der Poll T. Thrombomodulin mutant mice with a strongly reduced capacity to generate Activated Protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood. 2004;103:1702-1709.
68. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H, Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int. 2002;61:490-501.
69. Vasta GR, Quesenberry M, Ahmed H, O'Leary N. C-type lectins and galactins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev Comp Immunol. 1999;23: 401-420.
70. Dodd RB, Drickamer K. Lectin-like proteins in model organisms: implications for evolution of carbohydrate-binding activity. Glycobiology. 2001;11:71R-79R.
71. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002;196:565-577.
72. Van de Wouwer M, Clijsters K, Plaisance S, Collen D, Conway E. Establishing links between coagulation and inflammation: The lectin-like domain of thrombomodulin confers protection in a murine model of rheumatoid arthritis. J Thromb Haemost. 2003;1:266.
73. Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, Yang HY, Wu HL. Thrombomodulin-mediated cell adhesion: Involvement of its lectin-like domain. J Biol Chem. 2003.
74. Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunology. 1996;87:134-140.
75. Lohi O, Urban S, Freeman M. Diverse substrate recognition mechanisms for rhomboids: thrombomodulin is cleaved by mammalian rhomboids. Current Biology. 2004;14:236-241.
76. Boffa MC, Karmochkine M. Thrombomodulin: an overview and potential implications in vascular disorders. Lupus. 1998;7:S120-S125.
77. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999;353:1729-1734.
78. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol. 2003;14:373-375.
79. Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003;107:1729-1732.
80. Healy A, Rayburn H, Rosenberg R, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci (USA). 1995;92:850-854.
81. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9:331-337.
82. Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Bohrer H, Nakagawa M, Graeff H, Martin E, Stern D, Rosenberg R, Ziegler R, Nawroth P. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest. 1998;101:1301-1309.
83. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988;8:5588-5592.
84. Dittman WA, Kumada T, Majerus PW. Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin. Proc Natl Acad Sci U S A. 1989;86:7179-7182.
85. Maruyama I, Soejima Y, Osame M, Ito T, Ogawa K, Yamamoto S, Dittman WA, Saito H. Increased expression of thrombomodulin on the cultured human umbilical vein endothelial cells and mouse hemangioma cells by cyclic AMP. Thromb Res. 1991;61:301-310.
86. Maruyama I, Soejima Y. Upregulation of thrombomodulin on cultured endothelial cells by cAMP. Ann NY Acad Sci. 1990;598:538-539.
87. Weiler GH, Yu K, Soff G, Gudas LJ, Rosenberg RD. Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells. Proc Natl Acad Sci (USA). 1992;89:2155-2159.
88. Calnek DS, Grinnell BW. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res. 1998;238:294-298.
89. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor α-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14:575-585.
90. Malek AM, Jackman R, Rosenberg RD, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res. 1994;74:852-860.
91. Sperry JL, Deming CB, Bian C, Walinsky PL, Kass DA, Kolodgie FD, Virmani R, Kim AY, Rade JJ. Wall tension is a potent negative regulator of in vivo thrombomodulin expression. Circ Res. 2003;92:41-47.
92. Ohji T, Urano H, Shirahata A, Yamagishi M, Higashi K, Gotoh S, Karasaki Y. Transforming growth factor β1 and β2 induce down-modulation of thrombomodulin in human umbilical vein endothelial cells. Thromb Haemost. 1995;73:812-818.
93. Ishii H, Tezuka T, Ishikawa H, Takada K, Oida K, Horie S. Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARβ-RXRα heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. Blood. 2003;101:4765-4774.
94. Sandusky G, Berg DT, Richardson MA, Myers L, Grinnell BW. Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads. J Biol Chem. 2002;277:49815-49819.
95. Grey ST, Csizmadia V, Hancock WW. Differential effect of tumor necrosis factor-α on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells [In Process Citation]. Int J Hematol. 1998;67:53-62.
96. Moore, K.L., Esmon CT., Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73:159-165.
97. Glaser C, Morser J, Clarke J, Blasko E, McLean K, Kuhn I, Chang R-J, Lin J-H, Vilander L, Andrews W, Light D. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest. 1992;90:2565-2573.
98. Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood. 2000;95:1687-1693.
99. Xu J, Qu D, Esmon NL, Esmon CT. Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem. 2000;275:6038-6044.
100. Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem. 2000;275:5447-5452.
101. Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem. 1996;271:17499-17503.
102. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest. 1997;100:411-418.
103. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood. 1998;91:725-727.
104. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003;9:192-198.
105. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol. 2000;165:4697-4703.
106. Esmon CT. Structure and functions of the endothelial cell protein C receptor. Crit Care Med. 2004;32:S298-S301.
107. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, Esmon CT. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem. 2002;277:24851-24854.
108. Bajzar L, Nesheim M, Tracy P. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88:2093-2100.
109. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1:1343-1348.
110. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
111. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993;103:1536-1542.
112. Hartman D, Bernard G, Helterbrand J, Yan S, Fisher C. Recombinant human activated protein C (rfAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med. 1998;24:S77.
113. Schwarz HP, Ehrlich HJ. Activated protein C: more effective than nonactivated protein C? Crit Care Med. 2003;31:1597.
114. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med. 2003;31:S85-93.
115. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med. 2003;31:S94-S96.
116. Levi M, Choi G, Schools I, Schultz M, Van Der Poll T. Beyond sepsis: Activated protein C and ischemia-reperfusion injury. Crit Care Med. 2004;32:S309-S312.
117. Mohri M, Oka M, Aoki Y, Gonda Y, Hirata S, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol. 1994;45:298-303.
118. Gonda Y, Hirata S, Saitoh K, Aoki Y, Mohri M, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb Res. 1993;71:325-335.
119. Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost. 1995;74:1265-1270.
120. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood. 2004;103:1311-1318.